Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.54 |
| ▸ | TSHR | P16473 | 8/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10143034 | 0.86 | ALDH1A1 (0.44) | ALDH1A1TDP1TSHRCYP3A4RECQL | |
| SCHEMBL28531673 | 0.86 | ALDH1A1 (0.50) | ALDH1A1TDP1TSHRCYP3A4RECQL | |
| SCHEMBL27565474 | 0.81 | ALDH1A1 (0.40) | ALDH1A1TDP1TSHRCYP3A4RECQL | |
| SCHEMBL1820951 | 0.80 | ALDH1A1 (0.58) | ALDH1A1TDP1TSHRCYP3A4MEN1 | |
| SCHEMBL8440730 | 0.78 | TSHR (0.58) | ALDH1A1TDP1TSHRCYP3A4MEN1 | |
| SCHEMBL28420852 | 0.77 | ALDH1A1 (0.54) | ALDH1A1TDP1TSHRCYP3A4RECQL | |
| SCHEMBL11323444 | 0.76 | ALDH1A1 (0.54) | ALDH1A1TDP1TSHRCYP3A4MEN1 | |
| SCHEMBL487041 | 0.76 | ALDH1A1 (0.54) | ALDH1A1TDP1TSHRCYP3A4ALOX15 | |
| SCHEMBL540061 | 0.76 | ALDH1A1 (0.54) | ALDH1A1TDP1TSHRCYP3A4NPC1 | |
| SCHEMBL3781263 | 0.76 | TSHR (0.60) | ALDH1A1TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103508960-B | Benzheterocyclic derivatives | 江苏先声药业有限公司 | 2017-12-12 | — | — | CN | disclosed |
| US-8106079-B2 | Intermediate of 6-substituted-1-methyl-1-H-benzimidazole derivative and method for producing same | SANKYO COMPANY, LIMITED (JP) | 2012-01-31 | — | — | US | disclosed |
| US-7816552-B2 | Intermediate of 6-substituted 1-methyl-1-H-benzimidazole derivative and method for producing same | SANKYO COMPANY, LIMITED (JP) | 2010-10-19 | — | — | US | disclosed |
| US-20100234612-A1 | Intermediate of 6-substituted-1-methyl-1-H-benzimidazole derivative and method for producing same | SANKYO COMPANY, LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100063044-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2010-03-11 | — | — | US | disclosed |
| EP-1668002-B1 | 2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS | PORTOLA PHARM INC (US) | 2009-11-11 | — | — | EP | disclosed |
| US-7601870-B2 | Such as Hexanoic acid (4-bromo-2,6-dimethyl-phenyl)-amide; potassium channel modulators; epilepsy | H. LUNDBECK A/S (DK) | 2009-10-13 | — | — | US | disclosed |
| US-20090023929-A1 | Intermediate of 6-Substituted 1-Methyl-1-H-Benzimidazole Derivative and Method for Producing Same | SANKYO COMPANY, LIMITED (JP) | 2009-01-22 | — | — | US | disclosed |
| CN-101056845-A | Substituted aniline derivatives | LUNDBECK & CO AS H (DK) | 2007-10-17 | — | — | CN | disclosed |
| CN-101031565-A | Substituted 2H-1, 3-benzoxazin-4 (3H) -ones | PORTOLA PHARM INC (US) | 2007-09-05 | — | — | CN | disclosed |
| EP-0588060-B1 | Method for preparing aromatic secondary amino compound | MITSUI TOATSU CHEMICALS (JP) | 1997-04-02 | — | — | EP | disclosed |
| EP-0753505-A2 | Method for preparing aromatic secondary amino compound | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1997-01-15 | — | — | EP | disclosed |
| US-5536878-A | HYDROGEN ACCEPTOR | MITSUI TOATSU CHEMICALS, INC. (JP) | 1996-07-16 | — | — | US | disclosed |
| US-5382690-A | Method for preparing aromatic secondary amino compound | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1995-01-17 | — | — | US | disclosed |
| EP-0588060-A2 | Method for preparing aromatic secondary amino compound | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1994-03-23 | — | — | EP | disclosed |
| EP-0387106-B1 | Novel diamine compounds, production of the same and polyamideimide resins produced therefrom | TOMOEGAWA PAPER CO LTD (JP) | 1994-02-02 | — | — | EP | disclosed |
| US-5019642-A | Novel diamine compounds, production of the same and polyamideimide resins produced therefrom | TOMOEGAWA PAPER CO., LTD. (JP) | 1991-05-28 | — | — | US | disclosed |
| EP-0387106-A1 | Novel diamine compounds, production of the same and polyamideimide resins produced therefrom | TOMOEGAWA PAPER CO. LTD. (JP) | 1990-09-12 | — | — | EP | disclosed |
| EP-0103990-A1 | Process for making diarylamines | UNIROYAL, INC. (US) | 1984-03-28 | — | — | EP | disclosed |
| US-4431841-A | REACTING PRIMARY AROMATIC AMINES AND ALICYCLIC KETONES USING AN ACID PROMOTER AND A PLATINUM CATALYST | UNIROYAL, INC. (US) | 1984-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063044-A1 | SUBSTITUTED ANILINE DERIVATIVES | NDUFS3, NAT1, PRMT3 | ALDH1A1 206/4885TDP1 1999/4885TSHR 700/4885 |
| US-20090023929-A1 | Intermediate of 6-Substituted 1-Methyl-1-H-Benzimidazole Derivative and Method for Producing Same | AZI2, CYC1, CCNI | ALDH1A1 928/4885TDP1 2994/4885TSHR 3836/4885 |
| US-20100234612-A1 | Intermediate of 6-substituted-1-methyl-1-H-benzimidazole derivative and method for producing same | CYC1, CYP2B6, COX6B1 | ALDH1A1 668/4885TDP1 3676/4885TSHR 3351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.